Biomarker Study in Patients With Herpes Zoster
Inflammatory Cytokine and Neuropeptide Study in Patients With Herpes Zoster
1 other identifier
interventional
30
1 country
1
Brief Summary
Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin) in peripheral blood of participants with herpes zoster.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 15, 2022
CompletedFirst Posted
Study publicly available on registry
January 17, 2023
CompletedStudy Start
First participant enrolled
January 25, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2023
CompletedSeptember 25, 2025
July 1, 2023
9 months
December 15, 2022
September 21, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
serum level of inflammatory cytokine changes during 3 time period
inflammatory cytokine including Tumor necrosis factor-alpha, Interleukin-6 changes during 3 time period Higher score means worse outcome
Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
serum level of neurotransmitter changes during 3 time period
neurotransmitter including Calcitonene gene related peptide, substance P, vasoactive intestitinal polypeptide changes during 3 time period Higher score means worse outcome
Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
Secondary Outcomes (1)
Changes of numerical rating scale changes during 3 time period
Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
Study Arms (2)
herpes zoster (acute) patients with intervention
EXPERIMENTALPatients with herpes zoster receiving 2 times of nerve block
patients with chronic herpes zoster receiving 2 times of nerve block
EXPERIMENTALPatients with herpes zoster receiving 2 times of nerve block
Interventions
nerve block
Eligibility Criteria
You may qualify if:
- patients with NRS more than 4
- patients who failed medical treatment
- patients showing severe adverse reaction with medication
You may not qualify if:
- Patients showing allergic reaction to local anesthetics
- Patients with coagulation abnormality
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hong ji HEE
Daegu, 42601, South Korea
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 15, 2022
First Posted
January 17, 2023
Study Start
January 25, 2023
Primary Completion
October 30, 2023
Study Completion
November 30, 2023
Last Updated
September 25, 2025
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will not share